Lilly Says Safety Not A Factor In Dropping Lupus Development With Olumiant
Executive Summary The pharma also warns that an FDA complete response letter could be coming for its supplemental NDA to add atopic…
Executive Summary The pharma also warns that an FDA complete response letter could be coming for its supplemental NDA to add atopic…